奇努克治療公司
US ˙ NASDAQ ˙ US16961L1061
該符號不再有效

SecurityKDNY / Chinook Therapeutics Inc
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership21,953 shares
Latest Disclosed Value $ 10,537
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series ownership in KDNY / Chinook Therapeutics Inc

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 21,953 shares of Chinook Therapeutics Inc (US:KDNY) valued at $10,537 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 21,953 shares of Chinook Therapeutics Inc. This represents a change in shares of 0.00% during the quarter. The current value of the position is $886,682 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 11 0.00 0.0002
2025-05-28 2025-03-31 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 10 0.00 0.0002
2025-02-25 2024-12-31 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 10 0.00 0.0002
2024-11-26 2024-09-30 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 11 0.00 0.0002
2024-08-26 2024-06-30 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 10 0.00 0.0002
2024-05-28 2024-03-31 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 11 -81.82 0.0002
2024-02-26 2023-12-31 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 56 0.00 0.0012
2023-11-28 2023-09-30 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 0 0.00 56 0.00 0.0015
2023-08-25 2023-06-30 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 -78,411 -78.13 56 -98.57 0.0013
2023-08-25 2023-06-30 NP Chinook Therapeutics EC US16961L1061 100,364 78,411 357.18 3,856 6,909.09 0.0914
2023-05-26 2023-03-31 NP CONTRA ADURO BIOTECH I US007CVR0124 21,953 -58,783 -72.81 56 -97.06 0.0015
2023-05-26 2023-03-31 NP Chinook Therapeutics EC US16961L1061 80,736 58,783 267.77 1,869 3,298.18 0.0498
2023-02-24 2022-12-31 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -56,198 -71.91 56 -97.31 0.0015
2023-02-24 2022-12-31 NP Chinook Therapeutics EC US16961L1061 78,151 56,198 255.99 2,048 3,621.82 0.0563
2022-11-25 2022-09-30 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -56,247 -71.93 56 -96.42 0.0016
2022-11-25 2022-09-30 NP Chinook Therapeutics EC US16961L1061 78,200 56,247 256.22 1,537 2,694.55 0.0440
2022-08-25 2022-06-30 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -48,056 -68.64 56 -95.51 0.0015
2022-08-25 2022-06-30 NP Chinook Therapeutics EC US16961L1061 70,009 48,056 218.90 1,224 1,783.08 0.0338
2022-05-26 2022-03-31 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -40,418 -64.80 66 -93.63 0.0015
2022-05-26 2022-03-31 NP Chinook Therapeutics EC US16961L1061 62,371 40,418 184.11 1,020 1,469.23 0.0238
2022-02-25 2021-12-31 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -36,590 -62.50 66 -93.19 0.0014
2022-02-25 2021-12-31 NP Chinook Therapeutics EC US16961L1061 58,543 36,590 166.67 955 1,367.69 0.0207
2021-11-24 2021-09-30 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -25,074 -53.32 66 -89.17 0.0015
2021-11-24 2021-09-30 NP Chinook Therapeutics EC US16961L1061 47,027 25,074 114.22 600 823.08 0.0132
2021-08-26 2021-06-30 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 -25,074 -53.32 66 -90.21 0.0014
2021-08-26 2021-06-30 NP Chinook Therapeutics EC US16961L1061 47,027 25,074 114.22 664 921.54 0.0142
2021-05-27 2021-03-31 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 0 0.00 66 -80.94 0.0015
2021-05-27 2021-03-31 NP Chinook Therapeutics EC US16961L1061 21,953 0 0.00 341 424.62 0.0077
2021-02-25 2020-12-31 NP CONTRA ADURO BIOTECH I 007CVR012 21,953 0 0.00 66 -81.32 0.0017
2021-02-25 2020-12-31 NP Chinook Therapeutics EC US16961L1061 21,953 -87,815 -80.00 348 30.83 0.0089
2020-11-25 2020-09-30 NP Aduro Biotech EC US00739L1017 109,768 0 0.00 267 5.14 0.0086
2020-08-27 2020-06-30 NP Aduro Biotech EC US00739L1017 109,768 4,974 4.75 254 -11.85 0.0083
2020-06-01 2020-03-31 NP Aduro Biotech EC US00739L1017 104,794 9,278 9.71 287 156.25 0.0117
2020-02-27 2019-12-31 NP Aduro Biotech EC 00739L101 95,516 0 0.00 113 10.89 0.0034
2019-11-27 2019-09-30 NP Aduro Biotech EC US00739L1017 95,516 95,516 101 0.0033
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.